Clinical trial of insulin glargine injection combined with glimepiride tablets in the treatment of type 2 diabetes mellitus
10.13699/j.cnki.1001-6821.2018.03.018
- VernacularTitle:甘精胰岛素注射液联合格列美脲片治疗2型糖尿病的临床研究
- Author:
Dan-Dan ZHANG
1
;
Na SUN
;
Hui FANG
;
Ya-Zhong ZHANG
;
Jin-Li TIAN
;
Jing XU
;
He-Wei ZHANG
;
Gu-Yue ZHANG
;
Yan-Feng ZHEN
Author Information
1. 唐山市工人医院内分泌二科
- Keywords:
insulin glargine injection;
glimepiride tablet;
type 2 diabetes mellitus;
safety
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(3):251-253
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the clinical efficacy and safety of insulin glargine injection combined with glimepiride tablets in the treatment of type 2 diabetes mellitus (T2DM).Methods Forty-five patients with T2DM were randomly divided into control group (n =22 cases) and treatment group (n =23 cases).Control group was given insulin glargine with the starting dose of 0.2 U · kg-1,qd,subcutaneous injection.Treatment group was given glimepiride 2-4 mg,qd,orally,on the basis of the control group.Two groups were treated for 12 weeks.The blood glucose compliance rates and adverse drug reactions were compared between two groups.Results At 4,8,12 weeks after treatment,the blood glucose compliance rates in treatment group were 91.30％ (21 cases/23 cases),100.00％ (23 cases/23 cases) and 100.00％ (23 cases/23 cases),which in control group were 54.54％ (12 cases/22 cases),72.72％ (16 cases/22 cases) and 81.81％ (18 cases/22 cases),the differences were statistically significant (all P ＜ 0.05).The adverse drug reactions in treatment group were palpitation,which in control group were dizziness,palpitation,discomfort and sweating.The incidences of adverse drug reactions in treatment and control groups were 4.35％ and 31.82％ with significant difference (P ＜ O.05).Conclusion Insulin glargine injection combined with glimepiride tablets has a definitive clinical efficacy and safety in the treatment of T2DM,which can significantly improve the blood sugar compliance rate.
